Terms: = Kidney tumors AND VHL, HRCA1, P40337, 7428, ENSG00000134086, RCA1, VHL1 AND Treatment
408 results:
1. vhl loss reprograms the immune landscape to promote an inflammatory myeloid microenvironment in renal tumorigenesis.
Wolf MM; Madden MZ; Arner EN; Bader JE; Ye X; Vlach L; Tigue ML; Landis MD; Jonker PB; Hatem Z; Steiner KK; Gaines DK; Reinfeld BI; Hathaway ES; Xin F; Tantawy MN; Haake SM; Jonasch E; Muir A; Weiss VL; Beckermann KE; Rathmell WK; Rathmell JC
J Clin Invest; 2024 Apr; 134(8):. PubMed ID: 38618956
[TBL] [Abstract] [Full Text] [Related]
2. vhl governs m6A modification and PIK3R3 mRNA stability in clear cell renal cell carcinomas.
Lee H; Zhuang L; Gan B
J Clin Invest; 2024 Apr; 134(8):. PubMed ID: 38618953
[TBL] [Abstract] [Full Text] [Related]
3. Analysis of Factors Contributing to Adverse Events and Evaluation of Their Impact on Prognosis in Metastatic Renal Cell Carcinoma Patients-Real-World Experience in a Single-Center Retrospective Study and Narrative Review.
Domański P; Piętak M; Staneta S; Fortuniak W; Kruczyk B; Kobiernik A; Bakuła P; Mydlak A; Demkow T; Sikora-Kupis B; Dumnicka P; Kucharz J
Medicina (Kaunas); 2024 Feb; 60(3):. PubMed ID: 38541124
[No Abstract] [Full Text] [Related]
4. Hereditary Renal Cancer Syndromes.
Yanus GA; Kuligina ES; Imyanitov EN
Med Sci (Basel); 2024 Feb; 12(1):. PubMed ID: 38390862
[TBL] [Abstract] [Full Text] [Related]
5. Identification of genomic drivers for the therapeutic response of Cabozantinib in patients with metastatic renal cell carcinoma.
Borkowetz A; Sommer U; Baretton G; Gruellich C; Bürk BT; Erb HHH; Thomas C;
World J Urol; 2024 Feb; 42(1):94. PubMed ID: 38386122
[TBL] [Abstract] [Full Text] [Related]
6. vhl suppresses autophagy and tumor growth through PHD1-dependent Beclin1 hydroxylation.
Wang Z; Yan M; Ye L; Zhou Q; Duan Y; Jiang H; Wang L; Ouyang Y; Zhang H; Shen Y; Ji G; Chen X; Tian Q; Xiao L; Wu Q; Meng Y; Liu G; Ma L; Lei B; Lu Z; Xu D
EMBO J; 2024 Mar; 43(6):931-955. PubMed ID: 38360997
[TBL] [Abstract] [Full Text] [Related]
7. Percutaneous microwave ablation on management of hereditary renal cell carcinoma in Von Hippel-Lindau disease.
Chen J; Zheng L; Zhang W; Wang Z; Yu J; Liang P
Int J Hyperthermia; 2024; 41(1):2308079. PubMed ID: 38346873
[TBL] [Abstract] [Full Text] [Related]
8. Belzutifan, HIF-2α Inhibitor, and Clear Cell Renal Cell Carcinoma With Somatic Von-Hippel-Lindau Loss-of-Function Mutation.
Chan KH; Li N; Lador R; Amsbaugh M; Gonzalez A; Cen P
J Investig Med High Impact Case Rep; 2024; 12():23247096241231641. PubMed ID: 38344974
[TBL] [Abstract] [Full Text] [Related]
9. Targeting MYC induces lipid droplet accumulation by upregulation of HILPDA in clear cell renal cell carcinoma.
Sainero-Alcolado L; Garde-Lapido E; Snaebjörnsson MT; Schoch S; Stevens I; Ruiz-Pérez MV; Dyrager C; Pelechano V; Axelson H; Schulze A; Arsenian-Henriksson M
Proc Natl Acad Sci U S A; 2024 Feb; 121(7):e2310479121. PubMed ID: 38335255
[TBL] [Abstract] [Full Text] [Related]
10. [Activation of HIF-1α/ACLY signaling axis promotes progression of clear cell renal cell carcinoma with vhl inactivation mutation].
Ma Y; Wang YH; Huang S; Zou ZG; Hu L; Guo LC
Zhonghua Bing Li Xue Za Zhi; 2023 Dec; 52(12):1230-1236. PubMed ID: 38058039
[No Abstract] [Full Text] [Related]
11. The von Hippel-Lindau protein forms fibrillar amyloid assemblies that are mitigated by the anti-amyloid molecule Purpurin.
Kumar V; Kaushik V; Kumar S; Levkovich SA; Gupta P; Laor Bar-Yosef D; Gazit E; Segal D
Biochem Biophys Res Commun; 2024 Jan; 690():149250. PubMed ID: 38039781
[TBL] [Abstract] [Full Text] [Related]
12. Metformin Regulates the miR-205/VEGFA Axis in Renal Cell Carcinoma Cells: Exploring a Clinical Synergism with Tyrosine Kinase Inhibitors.
Krebs M; Kotlyar MJ; Fahl J; Janaki Raman S; Röhrig F; Marquardt A; Kübler H; Kneitz B; Schulze A; Kalogirou C
Urol Int; 2024; 108(1):49-59. PubMed ID: 38035560
[TBL] [Abstract] [Full Text] [Related]
13. The outcome of central nervous system hemangioblastomas in Von Hippel-Lindau (vhl) disease treated with belzutifan: a single-institution retrospective experience.
Zamarud A; Marianayagam NJ; Park DJ; Yener U; Yoo KH; Meola A; Chang SD
J Neurooncol; 2023 Nov; 165(2):373-379. PubMed ID: 37955759
[TBL] [Abstract] [Full Text] [Related]
14. Genomic Profiling and Molecular Characterization of Clear Cell Renal Cell Carcinoma.
Pezzicoli G; Ciciriello F; Musci V; Salonne F; Ragno A; Rizzo M
Curr Oncol; 2023 Oct; 30(10):9276-9290. PubMed ID: 37887570
[TBL] [Abstract] [Full Text] [Related]
15. Evolution of the HIF targeted therapy in clear cell renal cell carcinoma.
Golijanin B; Malshy K; Khaleel S; Lagos G; Amin A; Cheng L; Golijanin D; Mega A
Cancer Treat Rev; 2023 Dec; 121():102645. PubMed ID: 37879247
[TBL] [Abstract] [Full Text] [Related]
16. A Rare Presentation of Aggressive Renal Cell Carcinoma and the Utility of Early Molecular Testing in Rapidly Progressing Malignancies: A Case Report.
McLoughlin DE; Chevalier N; Choy E; Cote GM; Gao X; Juric D; Reynolds KL
Oncologist; 2023 Dec; 28(12):1094-1099. PubMed ID: 37844295
[TBL] [Abstract] [Full Text] [Related]
17. Population pharmacokinetic analyses for belzutifan to inform dosing considerations and labeling.
Marathe DD; Jauslin PM; Kleijn HJ; de Miranda Silva C; Chain A; Bateman T; Shaw PM; Abraham AK; Kauh EA; Liu Y; Perini RF; de Alwis DP; Jain L
CPT Pharmacometrics Syst Pharmacol; 2023 Oct; 12(10):1499-1510. PubMed ID: 37596839
[TBL] [Abstract] [Full Text] [Related]
18. PHF8-GLUL axis in lipid deposition and tumor growth of clear cell renal cell carcinoma.
Peng S; Wang Z; Tang P; Wang S; Huang Y; Xie Q; Wang Y; Tan X; Tang T; Yan X; Xu J; Lan W; Wang L; Zhang D; Wang B; Pan T; Qin J; Jiang J; Liu Q
Sci Adv; 2023 Aug; 9(31):eadf3566. PubMed ID: 37531433
[TBL] [Abstract] [Full Text] [Related]
19. Gene mutation profiling and clinical significances in patients with renal cell carcinoma.
Wang Y; He P; Zhou X; Wang C; Fu J; Zhang D; Liao D; Zhou Z; Wu C; Gong W
Clinics (Sao Paulo); 2023; 78():100259. PubMed ID: 37515929
[TBL] [Abstract] [Full Text] [Related]
20. Selective HIF2A Inhibitors in the Management of Clear Cell Renal Cancer and Von Hippel-Lindau-Disease-Associated tumors.
Suárez C; Vieito M; Valdivia A; González M; Carles J
Med Sci (Basel); 2023 Jun; 11(3):. PubMed ID: 37489462
[TBL] [Abstract] [Full Text] [Related]
[Next]
